Valuation: Gilead Sciences, Inc.

Market Cap 164B 143B 132B 121B 230B 15,752B 234B 1,576B 618B 7,683B 614B 601B 26,540B P/E 2026 *
-49.1x
P/E 2027 * 17.3x
Enterprise Value 173B 151B 140B 128B 243B 16,664B 247B 1,667B 654B 8,127B 649B 635B 28,076B EV / Sales 2026 *
5.68x
EV / Sales 2027 * 5.05x
Free-Float
99.88%
Yield 2026 *
2.38%
Yield 2027 * 2.47%
1 day+3.49%
1 week+0.35%
Current month+7.88%
1 month+9.65%
3 months-2.48%
6 months+12.40%
Current year+11.05%
1 week 127.94
Extreme 127.935
136.44
1 month 122.43
Extreme 122.43
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
6/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
6/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+3.49%+0.35%+24.98%+76.58% 164B
+1.08%-3.84%+51.50%+160.13% 1,031B
+1.19%-5.10%+61.09%+56.36% 595B
+4.21%+0.65%+36.48%+87.04% 431B
+0.42%-0.99%+30.04%+22.27% 326B
+1.03%-2.10%+28.32%+45.08% 277B
+0.49%-11.32%+20.31%+22.32% 263B
+1.59%+3.91%-22.47%-36.84% 224B
+3.70%+0.98%+27.03%+63.38% 193B
+1.29%+4.53%+2.15%-30.78% 141B
Average +1.52%-3.09%+25.94%+46.55% 364.58B
Weighted average by Cap. +1.18%-4.02%+36.41%+75.16%

Financials

2026 *2027 *
Net sales 30.47B 26.62B 24.63B 22.61B 42.77B 2,935B 43.54B 294B 115B 1,432B 114B 112B 4,945B 32.4B 28.31B 26.19B 24.04B 45.48B 3,121B 46.3B 312B 122B 1,522B 122B 119B 5,259B
Net income -3.39B -2.96B -2.74B -2.52B -4.76B -327B -4.85B -32.68B -12.82B -159B -12.73B -12.45B -550B 9.76B 8.53B 7.89B 7.24B 13.7B 940B 13.95B 94.07B 36.9B 459B 36.65B 35.85B 1,584B
Net Debt 9.46B 8.27B 7.65B 7.02B 13.28B 911B 13.52B 91.17B 35.76B 444B 35.52B 34.75B 1,536B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-16 $136.30 +3.49% 7,624,242
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
26-07-13 $131.40 +1.21% 5,131,594
26-07-10 $129.83 -3.72% 5,935,997
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
131.70USD
Average target price
158.30USD
Spread / Average Target
+20.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock